Phase I/IIa Study to Assess AllogeneiC Expanded Human Mesenchymal Stem Cell Therapy in Patients Recovering From COVID-19 Acute Respiratory Distress Trial (ACE CARD TRIAL)
Latest Information Update: 12 Oct 2023
Price :
$35 *
At a glance
- Drugs CardiALLO cell therapy (Primary)
- Indications Adult respiratory distress syndrome
- Focus Adverse reactions; First in man
- Acronyms ACE_CARD; Allogeneic NK1R+ MSC Trial in ARDS
- Sponsors BioCardia
- 10 May 2023 According to a BioCardia media release, trial is expected to commence in the fourth quarter of 2023.
- 29 Mar 2023 According to a BioCardia media release, while the number of patients with COVID-induced ARDS has decreased, ARDS, unrelated to COVID, is still significantly impacting patients. The Company intends to work with the FDA to modify the study eligibility criteria to include these patients.
- 29 Mar 2023 According to a BioCardia media release, Clinical-grade cells have been manufactured and are available for use in this study. This trial is expected to commence following the initiation of the trial studying these allogeneic MSC cells for HFrEF.